ID 202463510 · FY 2018–2024 · 7 years
Helios Pharma (ჰელიოს ფარმა) — a Tbilisi-based pharmaceutical depot and importer/representative of the Turkish 'Helios Pharmaceuticals' brand (vitamins, escitalopram, anti-parasitics and other therapeutic lines). Very high branded-representation margins (gross ~60–77%), but revenue collapsed after FY2022 (~GEL 8.4m to ~GEL 0.6m by 2024) — winding down. Assets (~GEL 12.8m) far exceed revenue, indicating non-operating assets/investments — treat balance-sheet ratios with care.
curated 2026-06-25
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,380 | 4,277 | 4,702 | 4,865 | 8,432 | 3,464 | 645 | -24.1% |
| Total COGS | -1,098 | -1,355 | -2,072 | -1,688 | -2,809 | -1,352 | -149 | -28.3% |
| Gross Profit | 2,281 | 2,923 | 2,630 | 3,177 | 5,623 | 2,112 | 496 | -22.5% |
| Gross Margin | 67.5% | 68.3% | 55.9% | 65.3% | 66.7% | 61.0% | 76.8% | |
| Total Operating Expenses | -750 | -844 | -727 | -600 | -573 | -463 | -246 | -17.0% |
| EBITDA | 1,531 | 2,078 | 1,902 | 2,577 | 5,050 | 1,649 | 250 | -26.1% |
| EBITDA Margin | 45.3% | 48.6% | 40.5% | 53.0% | 59.9% | 47.6% | 38.7% | |
| Total D&A | -3 | -3 | -3 | -1 | -0 | -1 | -3 | +1.2% |
| EBIT / Operating Income | 1,528 | 2,075 | 1,900 | 2,577 | 5,049 | 1,648 | 247 | -26.2% |
| Total Interest Income | 0 | 0 | 33 | 193 | 297 | 286 | 411 | +87.4% |
| Total Other Income | 0 | 0 | 343 | -126 | -100 | 90 | -178 | nmf |
| Profit Before Tax | 1,528 | 2,075 | 2,276 | 2,644 | 5,247 | 2,024 | 479 | -17.6% |
| Total Income Tax | -230 | -312 | -336 | -369 | 0 | -113 | 0 | -13.2% |
| Net Profit / (Loss) | 1,301 | 1,766 | 1,910 | 2,082 | 4,950 | 1,626 | 72 | -38.3% |
| Net Margin | 38.5% | 41.3% | 40.6% | 42.8% | 58.7% | 46.9% | 11.1% |
Ownership & directors from companyinfo.ge (public corporate registry).